GlobeNewsWire
30 Jun 2026, 16:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA issued a second Complete Response Letter (CRL) regarding Unicycive Therapeutics' resubmitted OLC NDA. — A second CRL indicates a failure to gain regulatory approval for a key product, significantly delaying potential revenue and impacting company valuation.
-0.90The FDA's rejection was based on recurring third-party manufacturing deficiencies and a lack of a completed vendor inspection. — Recurring deficiencies suggest systemic operational failures and uncertainty regarding the timeline for a successful resubmission.
-0.60Law firm Johnson Fistel is investigating Unicycive Therapeutics for potential securities law violations following investor losses. — Legal investigations into misleading statements can lead to costly settlements or litigation, creating additional financial overhang for the company.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company received a second FDA Complete Response Letter due to manufacturing deficiencies, leading to a stock price decline and a legal investigation.
The company is the subject of an investigation by Johnson Fistel on behalf of investors who suffered losses.
The company is the subject of an investigation by Johnson Fistel on behalf of investors who suffered losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
20h ago
